Article
Triple combination therapy for hepatitis C with telaprevir exhibits greater early antiviral activity than with boceprevir.
Antiviral therapy - 1 Jan 2013
Benito José M, Sánchez-Parra Clara, Maida Ivana, Aguilera Antonio, Rallón Norma I, Rick Fernanda, Labarga Pablo, Fernández-Montero José V, Barreiro Pablo, Soriano Vincent
Abstract excerpt
BACKGROUND: Achievement of early viral suppression is important in patients with chronic HCV infection treated with telaprevir (TLV) or boceprevir (BOC) to avoid selection of drug resistance and attain cure. No head-to-head studies comparing TLV and BOC have been performed so far. METHODS: All consecutive individuals who initiated triple HCV therapy with TLV or BOC outside clinical trials at three European...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.